Beneficial Effects of the Ketogenic Diet on Nonalcoholic Fatty Liver Disease (NAFLD/MAFLD) DOI Open Access
Damian Dyńka,

Łukasz Rodzeń,

Mateusz Rodzeń

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(16), P. 4857 - 4857

Published: Aug. 17, 2024

The prevalence of nonalcoholic fatty liver disease (NAFLD) is likely to be approaching 38% the world's population. It predicted become worse and main cause morbidity mortality due hepatic pathologies. particularly worrying that NAFLD increasingly diagnosed in children closely related, among other conditions, insulin resistance metabolic syndrome. Against this background concern awareness patients with low; one study, almost 96% adult USA were not aware their disease. Thus, studies on therapeutic tools used treat are extremely important. One promising treatment a well-formulated ketogenic diet (KD). aim paper present review available publications current state knowledge effect KD NAFLD. This includes characteristics key factors (from point view regression), which exerts its effects, i.e., reduction body weight, elimination fructose monosaccharides, limitation total carbohydrate intake, anti-inflammatory ketosis state, or modulation gut microbiome metabolome. In context evidence for effectiveness regression NAFLD, also suggests important role taking responsibility one's own health through increasing self-monitoring self-education.

Language: Английский

Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort DOI
Jesse A. Goodrich, Douglas I. Walker, Xiangping Lin

et al.

JHEP Reports, Journal Year: 2022, Volume and Issue: 4(10), P. 100550 - 100550

Published: Aug. 8, 2022

Language: Английский

Citations

80
Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol DOI Creative Commons
Ming Yang, Xiaoqiang Qi, Nan Li

et al.

Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)

Published: Jan. 16, 2023

Abstract The interplay between western diet and gut microbiota drives the development of non-alcoholic fatty liver disease its progression to steatohepatitis. However, specific microbial metabolic mediators contributing steatohepatitis remain be identified. Here, a choline-low high-fat high-sugar diet, representing typical named CL-HFS, successfully induces male mouse with some features human disease, such as hepatic inflammation, steatosis, fibrosis. Metataxonomic metabolomic studies identify Blautia producta 2-oleoylglycerol clinically relevant bacterial CL-HFS-induced In vivo validate that both promote inflammation fibrosis in normal diet- or CL-HFS-fed mice. Cellular molecular reveal GPR119/TAK1/NF-κB/TGF-β1 signaling pathway mediates 2-oleoylglycerol-induced macrophage priming subsequent stellate cell activation. These findings advance our understanding pathogenesis provide targets for developing microbiome/metabolite-based therapeutic strategies against

Language: Английский

Citations

59
Gut microbiota alters host bile acid metabolism to contribute to intrahepatic cholestasis of pregnancy DOI Creative Commons
Bo Tang, Li Tang, Shengpeng Li

et al.

Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)

Published: March 9, 2023

Abstract Intrahepatic cholestasis of pregnancy (ICP) is a female pregnancy-specific disorder that characterized by increased serum bile acid and adverse fetal outcomes. The aetiology mechanism ICP are poorly understood; thus, existing therapies have been largely empiric. Here we show the gut microbiome differed significantly between individuals with healthy pregnant women, colonization from patients was sufficient to induce in mice. microbiomes were primarily Bacteroides fragilis ( B. ), able promote inhibiting FXR signaling via its BSH activity modulate metabolism. -mediated inhibition responsible for excessive synthesis interrupted hepatic excretion ultimately initiation ICP. We propose modulation microbiota-bile acid-FXR axis may be value treatment.

Language: Английский

Citations

58
Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies DOI Creative Commons

Marta Maestri,

Francesco Santopaolo, Maurizio Pompili

et al.

Frontiers in Nutrition, Journal Year: 2023, Volume and Issue: 10

Published: Feb. 16, 2023

Non-alcoholic fatty liver disease (NAFLD) is frequently associated with metabolic disorders, being highly prevalent in obese and diabetic patients. Many concomitant factors that promote systemic inflammation are involved NAFLD pathogenesis, a growing body of evidence highlighting the key role gut microbiota. Indeed, gut-liver axis has strong impact promotion progression wide spectrum its manifestations, claiming efforts to find effective strategies for microbiota modulation. Diet among most powerful tools; Western diet negatively affects intestinal permeability composition function, selecting pathobionts, whereas Mediterranean fosters health-promoting bacteria, favorable on lipid glucose metabolism inflammation. Antibiotics probiotics have been used improve features, mixed results. More interestingly, medications treat NAFLD-associated comorbidities may also modulate Drugs treatment type 2 diabetes mellitus (T2DM), such as metformin, glucagon-like peptide-1 (GLP-1) agonists, sodium-glucose cotransporter (SGLT) inhibitors, not only regulation homeostasis, but reduction fat content inflammation, they shift towards healthy phenotype. Even bariatric surgery significantly changes microbiota, mostly due modification gastrointestinal anatomy, parallel improvement histological features NAFLD. Other options promising effects reprogramming axis, fecal microbial transplantation (FMT) next-generation deserve further investigation future inclusion therapeutic armamentarium

Language: Английский

Citations

49
Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation DOI Creative Commons

Byeong Hyun Min,

Shivani Devi,

Goo Hyun Kwon

et al.

Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)

Published: Feb. 1, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic disease, and its prevalence has increased worldwide in recent years. Additionally, there a close relationship between MASLD gut microbiota-derived metabolites. However, mechanisms of metabolites are still unclear. We demonstrated decreased indole-3-propionic acid (IPA) indole-3-acetic (IAA) feces patients with hepatic steatosis compared to healthy controls. Here, IPA IAA administration ameliorated inflammation an animal model WD-induced by suppressing NF-κB signaling pathway through reduction endotoxin levels inactivation macrophages. Bifidobacterium bifidum metabolizes tryptophan produce IAA, B. effectively prevents production IAA. Our study demonstrates that derived from microbiota have novel preventive or therapeutic potential for treatment.

Language: Английский

Citations

37
Gut microbiota and metabolic biomarkers in metabolic dysfunction–associated steatotic liver disease DOI Creative Commons
Qichen Long, Fengming Luo, Binghui Li

et al.

Hepatology Communications, Journal Year: 2024, Volume and Issue: 8(3)

Published: Feb. 26, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), a replacement of the nomenclature employed for NAFLD, is most prevalent chronic worldwide. Despite its high global prevalence, NAFLD often under-recognized due to absence reliable noninvasive biomarkers diagnosis and staging. Growing evidence suggests that gut microbiome plays significant role in occurrence progression by causing immune dysregulation metabolic alterations dysbiosis. The rapid advancement sequencing tools metabolomics has enabled identification signatures microbiota-derived metabolite profiles numerous clinical studies related NAFLD. Overall, these have shown decrease α-diversity changes microbiota abundance, characterized increased levels Escherichia Prevotella, decreased Akkermansia muciniphila Faecalibacterium patients with Furthermore, bile acids, short-chain fatty trimethylamine N-oxide, tryptophan metabolites are believed be closely associated onset In this review, we provide novel insights into vital pathogenesis Specifically, summarize major classes thereby highlighting links between specific bacterial species certain

Language: Английский

Citations

23
Chlorogenic Acid Improves NAFLD by Regulating gut Microbiota and GLP-1 DOI Creative Commons

Ameng Shi,

Ting Li,

Ying Zheng

et al.

Frontiers in Pharmacology, Journal Year: 2021, Volume and Issue: 12

Published: June 30, 2021

Our previous studies have shown that chlorogenic acid (CGA) could significantly improve acute and chronic liver injury through antioxidant anti-inflammatory activities. However, its effect on non-alcoholic fatty disease (NAFLD) are not entirely clear. This study aims to explore the of CGA NAFLD induced by high-fat diet (HFD) whether it regulates gut microbiota Glucagon-like peptide-1 (GLP-1). mice were established HFD treated with or without CGA. Serum transaminase, fasting blood glucose (FBG), lipids, insulin, GLP-1 lipopolysaccharide (LPS) detected. Liver histology was evaluated Hematoxylin-eosin staining. Toll like receptor 4 (TLR4) signaling pathway analyzed western blot inflammatory cytokines detected real-time PCR. The content determined PCR bacterial 16S rRNA gene. Expressions intestine tight junctional protein examined immunohistochemistry. alleviate HFD-induced hepatic steatosis inflammation, reduce serum FBG increase insulin sensitivity. also reverse activation TLR4 expression tumor necrosis factor-α (TNF-α) interleukin-6 (IL-6) in liver. Meanwhile, increased Bifidobacterium reduced

Language: Английский

Citations

97
Effect of Probiotics on Liver Enzymes in Patients With Non-alcoholic Fatty Liver Disease: An Umbrella of Systematic Review and Meta-Analysis DOI Creative Commons
Vali Musazadeh, Neda Roshanravan, Parvin Dehghan

et al.

Frontiers in Nutrition, Journal Year: 2022, Volume and Issue: 9

Published: May 23, 2022

Non-alcoholic fatty liver disease (NAFLD) has become prevalent in recent decades, especially developed countries; yet the approaches for preventing and treating NAFLD are not clear. This study aimed to summarize meta-analyses of randomized controlled trials that examined effects probiotics on NAFLD. We systematically searched PubMed, Scopus, Embase, Web Science, Cochrane Central Library databases up August 2021. All Meta-analysis studies assessing effect function tests [alanine aminotransferase (ALT), aspartate (AST), Gamma-glutamyl transferase (GGT)] were included. was conducted using a random-effects model. Sensitivity subgroup analyses also performed. The umbrella covered ten eligible involving 5,162 individuals. Beneficial supplementation revealed ALT (ES = −10.54 IU/L; 95% CI: −12.70, −8.39; p < 0.001; I 2 60.9%, 0.006), AST −10.19 IU/L, 95%CI: −13.08, −7.29, 79.8%, 0.001), GGT −5.88 −7.09, −4.67, 0.009; 0.0%, 0.591) levels. Probiotics have ameliorating ALT, AST, levels patients with Overall, could be recommended as an adjuvant therapeutic method management

Language: Английский

Citations

39
Efficacy of probiotics on nonalcoholic fatty liver disease: A meta-analysis DOI Creative Commons
Xiangyu Zhou, Jincheng Wang,

Sufang Zhou

et al.

Medicine, Journal Year: 2023, Volume and Issue: 102(4), P. e32734 - e32734

Published: Jan. 27, 2023

The intestinal flora is closely related to the pathogenesis of nonalcoholic fatty liver disease (NAFLD). This study intends systematically evaluate efficacy and safety probiotics in treatment NAFLD through a meta-analysis published randomized controlled trials.

Language: Английский

Citations

29
Lactobacillus plantarum ZJUIDS14 alleviates non-alcoholic fatty liver disease in mice in association with modulation in the gut microbiota DOI Creative Commons

Feiwei Cao,

Qinchao Ding,

Hui Zhuge

et al.

Frontiers in Nutrition, Journal Year: 2023, Volume and Issue: 9

Published: Jan. 9, 2023

This present study was designed to explore the protective role of Lactobacillus plantarum ZJUIDS14 against Non-alcoholic Fatty Liver Disease (NAFLD) in a high-fat-diet (HFD)-induced C57BL/6 mice model. The probiotic (109 CFU/every other day) administered by oral gavage for 12 weeks. We found that L. intervention significantly alleviated HFD related hepatic steatosis, liver damage, insulin resistance, and increased expression peroxisome proliferator activated receptor α (PPAR-α) while stimulating activation AMP-activated protein kinase (AMPK). Furthermore, improved mitochondrial function as reflected an increase dynamin 1 (DRP1) decrease proteins associated with oxidative phosphorylation (OXPHOS) after treatment. Additionally, from group had restored intestinal flora homeostasis involving Coprostanoligenes group, Ruminococcaceae UCG-014, Allobaculum, Ruminiclostridium 1, Roseburia. Meanwhile, these five genera exhibited significant (negative or positive) association ileum inflammation mRNA levels SCFA contents, Spearman's correlation analysis. In general, our data demonstrated mitigates steatosis damage induced HFD. Specifically, they strengthened integrity barrier, regulated gut microbiota, function. Our provide experimental basis promising candidate prevent NAFLD.

Language: Английский

Citations

26